ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0310

Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis

TING WANG, Natalia V. Giltiay, Christian Lood and Bobby Kwanghoon Han, Division of Rheumatology, University of Washington, Seattle, WA

Meeting: ACR Convergence 2022

Keywords: Biomarkers, clinical trial, rheumatoid arthritis, T Cell

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 12, 2022

Title: RA – Treatment Poster I

Session Type: Poster Session A

Session Time: 1:00PM-3:00PM

Background/Purpose: Activation of T cells plays a key role in the pathogenesis of rheumatoid arthritis (RA), which is characterized by inflammation of the synovial tissue and autoantibody production. Abatacept, a CTLA-4-Ig fusion protein that targets CD80/CD86 and CD28 interaction and therefore interferes with T cell activation, is widely used as a treatment of RA. However, the response rates to abatacept are variable in heterogeneous RA patients and there are limited data on biomarkers associated with therapeutic response. We conducted this study to assess the therapeutic effects of abatacept on different T cell and B cell subsets in peripheral blood and to identify predictive biomarkers of the therapeutic efficacy of abatacept in patients with moderate to severe RA.

Methods: A total of 20 patients with RA were enrolled in this study. All participants fulfilled the 1987 ACR criteria or 2010 ACR/EULAR criteria, with clinical disease activity index (CDAI) ≥16. Peripheral blood mononuclear cells (PBMCs) were isolated and analyzed by flow cytometry at baseline, week 14 and week 24. Responders were defined as subjects who achieved ACR50 Response at week 24. Percentages of different T cell and B cell subsets were compared between the responder and non-responder groups.

Results: At week 24, subjects treated with abatacept had a significant decline in the frequencies of circulating CD4+CXCR5+PD-1hi follicular helper T (Tfh) cells (p< 0.0001), CD4+CXCR5–PD-1hi peripheral helper T (Tph) cells (p< 0.0001) and CD4+PD-1+ T cells (p=0.0001). Abatacept dramatically reduced the expression of inducible costimulatory molecule (ICOS) in Tfh cells and Tph cells (p< 0.0001). Only the frequencies of CD4+CXCR5+CXCR3+CCR6– Tfh-Th1 cells were decreased (p< 0.01) among the Tfh subsets. There was also reduction in other T cell subsets, including CD4+CD25+CD127– regulatory T (Treg) cells (p< 0.0001) and CD4+CD45RA–CCR7– effector memory T cells (p< 0.01). Abatacept also reduced the frequencies of circulating CD19+IgD–CD27+ class-switched memory B cells and CD19+IgD–CD27– double negative B cells (p=0.0128 and p=0.0184, respectively) after 24-week treatment. Eight patients (40%) achieved ACR 50 response with abatacept at week 24. Compared to the non-responders, the responders had numerically higher percentage of anti-CCP antibodies (88% vs 58%, p=0.325) and rheumatoid factor (88% vs 50%, p=0.158). Baseline frequencies of Tfh cells (p=0.0457) and CD4+PD1+ T cells (p=0.0574) were higher in responders compared to non-responders (Figure 1).

Conclusion: These findings identify CD4+CXCR5+PD-1hi Tfh cells as a potential biomarker in predicting the therapeutic efficacy of abatacept in RA patients.

Supporting image 1

Figure 1. Frequencies of circulating CD4+CXCR5+PD_1hi Tfh cells predict the therapeutic efficacy of abatacept in RA patients. Comparison of the proportions of CD4+CXCR5+PD_1hi Tfh (A) and CD4+PD_1+ T cells (B) in circulation at baseline in patients treated with abatacept. Responders were defined as subjects who achieved ACR50 Response at week 24. Differences between groups were determined by Mann Whitney test. P<0.05 was considered statistically significant.


Disclosures: T. WANG, None; N. Giltiay, None; C. Lood, Eli Lilly, Gilead Sciences, Pfizer, Bristol-Myers Squibb(BMS), Redd Pharma, Horizon Diagnostic, Exagen Diagnostic; B. Han, None.

To cite this abstract in AMA style:

WANG T, Giltiay N, Lood C, Han B. Higher Baseline Circulating CD4+CXCR5+PD-1hi Follicular Helper T Cells Predict Therapeutic Efficacy of Abatacept in Moderate to Severe Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2022; 74 (suppl 9). https://acrabstracts.org/abstract/higher-baseline-circulating-cd4cxcr5pd-1hi-follicular-helper-t-cells-predict-therapeutic-efficacy-of-abatacept-in-moderate-to-severe-rheumatoid-arthritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2022

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-baseline-circulating-cd4cxcr5pd-1hi-follicular-helper-t-cells-predict-therapeutic-efficacy-of-abatacept-in-moderate-to-severe-rheumatoid-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology